Format

Send to

Choose Destination
J Natl Compr Canc Netw. 2016 Jan;14(1):19-30.

Prostate Cancer, Version 1.2016.

Author information

1
From Roswell Park Cancer Institute; Duke Cancer Institute; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Dana-Farber/Brigham and Women's Cancer Center; Mayo Clinic Cancer Center; Memorial Sloan Kettering Cancer Center; Fred & Pamela Buffett Cancer Center; Prostate Health Education Network (PHEN); Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Fox Chase Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; UC San Diego Moores Cancer Center; City of Hope Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Vanderbilt-Ingram Cancer Center; Moffitt Cancer Center; University of Colorado Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California San Francisco Patient Services Committee Chair; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Michigan Comprehensive Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Stanford Cancer Institute; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Huntsman Cancer Institute at the University of Utah; and National Comprehensive Cancer Network.

Abstract

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.

Comment in

PMID:
26733552
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center